Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)

Vasomotor Symptoms ◽

Double Blind ◽

Patient Reported ◽

Dose Ranging ◽

The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: a randomized, placebo-controlled, double-blind, dose-ranging study

Maturitas ◽

10.1016/j.maturitas.2019.04.081 ◽

2019 ◽

Vol 124 ◽

pp. 135

Author(s):

Graeme Fraser ◽

Samuel Lederman ◽

Arthur Waldbaum ◽

Misun Lee ◽

Laurence Skillern ◽

...

Keyword(s):

Receptor Antagonist ◽

Vasomotor Symptoms ◽

Double Blind ◽

Dose Ranging ◽

The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: responder analysis results from a randomized, placebo-controlled, double-blind, dose-ranging study

Endocrine Abstracts ◽

10.1530/endoabs.63.oc8.5 ◽

2019 ◽

Author(s):

Graeme Fraser ◽

Samuel Lederman ◽

Arthur Waldbaum ◽

James Young ◽

Laurence Skillern ◽

...

Keyword(s):

Receptor Antagonist ◽

Vasomotor Symptoms ◽

Double Blind ◽

Responder Analysis ◽

Dose Ranging ◽

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause

Menopause ◽

10.1097/gme.0000000000001510 ◽

2020 ◽

Vol 27 (4) ◽

pp. 382-392 ◽

Cited By ~ 6

Author(s):

Graeme L. Fraser ◽

Samuel Lederman ◽

Arthur Waldbaum ◽

Robin Kroll ◽

Nanette Santoro ◽

...

Keyword(s):

Receptor Antagonist ◽

Vasomotor Symptoms ◽

Double Blind ◽

Dose Ranging ◽

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study

Journal of the Endocrine Society ◽

10.1210/js.2019-or33-6 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

Cited By ~ 1

Author(s):

Graeme Fraser ◽

Samuel Lederman ◽

Arthur Waldbaum ◽

Misun Lee ◽

Laurence Skillern ◽

...

Keyword(s):

Receptor Antagonist ◽

Vasomotor Symptoms ◽

Double Blind ◽

Dose Ranging ◽

Faculty Opinions recommendation of Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726641973.793540485 ◽

2017 ◽

Author(s):

Lori Ann Birder

Keyword(s):

Overactive Bladder ◽

Phase Ii ◽

Combination Treatment ◽

Phase Ii Study ◽

Double Blind ◽

Patient Reported ◽

Dose Ranging

Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)

World Journal of Urology ◽

10.1007/s00345-016-1908-1 ◽

2016 ◽

Vol 35 (5) ◽

pp. 827-838 ◽

Cited By ~ 20

Author(s):

P. Abrams ◽

C. Kelleher ◽

D. Staskin ◽

R. Kay ◽

A. Martan ◽

...

Keyword(s):

Overactive Bladder ◽

Phase Ii ◽

Combination Treatment ◽

Phase Ii Study ◽

Double Blind ◽

Patient Reported ◽

Dose Ranging

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.95 ◽

2017 ◽

Vol 1 ◽

pp. s96

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Patient Reported

Abstract Not AvailableDisclosure: Study supported by Dermira.

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.41 ◽

2018 ◽

Vol 2 ◽

pp. S41

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Patient Reported

Abstract not available. Disclosures: Study supported by Dermira. Copyright SKIN 2018

A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study of the Calcium-Sensing Receptor Antagonist MK-5442 in the Treatment of Postmenopausal Women With Osteoporosis

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2013-4009 ◽

2014 ◽

Vol 99 (11) ◽

pp. E2207-E2215 ◽

Cited By ~ 31

Author(s):

Johan Halse ◽

Susan Greenspan ◽

Felicia Cosman ◽

Graham Ellis ◽

Arthur Santora ◽

...

Keyword(s):

Receptor Antagonist ◽

Postmenopausal Women ◽

Phase 2 ◽

Calcium Sensing Receptor ◽

Calcium Sensing ◽

Dose Ranging

Patient‐Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis Care & Research ◽

10.1002/acr.22044 ◽

2013 ◽

Vol 65 (10) ◽

pp. 1666-1673 ◽

Cited By ~ 16

Author(s):

Arthur Kavanaugh ◽

Iain B. McInnes ◽

Gerald G. Krueger ◽

Dafna Gladman ◽

Anna Beutler ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Clinical Response ◽

Controlled Trial ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Patient Reported